Biosplice Therapeutics's logo

Biosplice Therapeutics Stock and Valuation

Pharmaceuticals and Biotechnology
Year Founded
2008
Headquarters
San Diego, CA
Employees
123

Biosplice Therapeutics Valuation Estimate

Based on UpMarket valuation model
$12.66 billion

Biosplice Therapeutics Valuation as of Last Funding Round

As of 08/06/18, according to PitchBook Data, Inc.
$12.44 billion

Want to buy Biosplice Therapeutics stock?

UpMarket has helped our customers invest over $140 million into private markets.

Biosplice Therapeutics Company Overview

Established in 2009 by Osman Kibar, Biosplice's mission is to restore health by providing the finest medicines based on alternative splicing. Their scientific platform is based on biological discoveries that govern tissue specialization. It enables them to eliminate harmful proteins using small molecules selectively. Biosplice's primary focuses are on treatments for osteoarthritis and oncology. However, they are also in the early stages of developing programs in neurology and other areas.

Biosplice Therapeutics Valuation History

Biosplice Therapeutics Stock Price

The stock price of Biosplice Therapeutics can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.

For illustrative purposes, however, assuming Biosplice Therapeutics has issued 250 million shares, at the estimated UpMarket valuation of $12.66 billion, each share of Biosplice Therapeutics stock would be worth $50.65.

Buy Biosplice Therapeutics Stock

If you would like to buy shares in Biosplice Therapeutics, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”

One of our investor relations team members will contact you to discuss Biosplice Therapeutics stock availability. Note: inquiries are non-binding and shares may only be purchased by accredited investors that meet all eligibility criteria.

UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Biosplice Therapeutics as well.

Biosplice Therapeutics Management

Name Position
Cevdet Samikoglu CEO
Scott Bulcao CLO
Erich Horsley CFO

Biosplice Therapeutics Investors

Sands Capital

Upgrade, Scopely, StockX, Credo AI, BYJU'S, Lyra, Snyk, Klaviyo, PolyAI, Outreach, Gusto, DataRobot

Vast Ventures

Ripple, Tala, Asapp, Zocdoc

Forepont Capital Partners

Synchron

IKEA

Northvolt

Verition Fund Management

BYJU'S

Biosplice Therapeutics SEC Activities/Filings

Form SEC Filings Date
D Notice of Exempt Offering of Securities 08/24/22
D Notice of Exempt Offering of Securities 03/03/21

Biosplice Therapeutics Related Companies

About UpMarket

UpMarket's mission is to unlock the private markets for individual investors.

We provide access to a range of asset classes and investment strategies that span private equity, hedge funds, crypto, real estate, and other alternative assets.

The problem

Historically, accessing private market investments had these challenges:
  • A large barrier to entry due to high investment minimums
  • Time-intensive because sourcing deals is a lot of work even if you’ve got a great network, and
  • Costly because of investment-related diligence costs, paperwork, and legal fees

The solution

UpMarket works to address these barriers for individual investors by:
  • Offering lower investment minimums
  • Sourcing and conducting diligence on opportunities for investors, empowering them to pick and choose from pre-screened opportunities
  • Making the investment process entirely digital, straightforward, and easy to manage from a single portal
Individuals like you have invested over $140 Million with UpMarket.

UpMarket Investment Curation Process

Upmarket curates and conducts diligence on every investment opportunity we offer.

We review every offering’s strategy, risk management, liquidity management, fees and expenses, valuation methodology, tax matters, as well as the fund’s third-party providers including legal counsel, auditor, administrator, and custodian.

We aim to offer our clients investments from disciplined managers that pursue unique strategies across an array of asset classes.

Our goal is to empower you to build a portfolio that best meets your individual Investment objectives.

Unlock the private markets today, with UpMarket.